Skip to content Skip to footer

Tag: precision oncology

HomeAll PostsTag: precision oncology
Parabilis Medicines, Inc. (NASDAQ: PBLS) entered public markets with the kind of financial runway, strategic endorsement and clinical ambition that tends to make biotech investors sit up straighter in their Aeron chairs. The Cambridge-based clinical-stage company is pursuing a deceptively simple proposition: use…
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) delivered the sort of update growth investors prefer: higher guidance, record revenue, expanding treatment access, and a more visible route toward operating leverage. Shares climbed sharply after the company lifted its 2026 revenue outlook, suggesting Wall Street is…